

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Berger et al.

Application No. 09/936,702

Filed: September 13, 2001

Confirmation No. 9274

For: A NOVEL CHIMERIC PROTEIN FOR  
PREVENTION AND TREATMENT OF  
HIV INFECTION

Examiner: Robert A. Zeman

Art Unit: 1645

Attorney Reference No. 4239-60771-01

MAIL STOP RCE  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP RCE, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent  
for Applicant(s)

A handwritten signature in black ink, appearing to read "Anne Carlson", written over a horizontal line.

Date Mailed September 10, 2004

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(4)


Listed on the accompanying form PTO-1449 and enclosed herewith are twelve English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants are filing this Information Disclosure Statement ("IDS") along with a Request for Continued Examination. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, deposit account authority is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By   
Anne Carlson, Ph.D.  
Registration No. 47,472

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446



**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Attorney Docket Number	4239-60771-01
Application Number	09/936,702
Filing Date	September 13, 2001
First Named Inventor	Berger
Art Unit	1645
Examiner Name	Robert A. Zeman

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,591,828	7 Jan 1997	Bosslet <i>et al.</i>
		5,925,741	20 July 1999	Gershoni
		6,020,468	1 Feb 2000	Gershoni
		6,143,876	7 Nov 2000	Gershoni
		6,329,202	11 Dec 2001	Gershoni
		6,410,318	25 June 2002	Gershoni

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		EPC	0 739 904	30 Oct 1996	Medarex, Inc.

**OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
		DEY <i>et al.</i> , <i>J. Virol.</i> 77(5):2859-2865, 2003
		LIAO <i>et al.</i> , <i>J. Virol.</i> 78(10):5270-5278, 2004
		ROEHR, <i>American Foundation for AIDS Research</i> , 3(4):1-8, 2002 (www.amfar.org/td)
		SALZWEDEL <i>et al.</i> , <i>J. Virol.</i> 74(1):326-333, 2000
		VERMEIRE <i>et al.</i> , <i>J. Leukocyte Biol.</i> 74:667-675, 2003

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.